Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK8 | P49336 | 1/20 | 0.51 |
| ▸ | DYRK1B | Q9Y463 | 5/20 | 0.46 |
| ▸ | CLK1 | P49759 | 2/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.46 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.45 |
| ▸ | EP300 | Q09472 | 1/20 | 0.43 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 3/20 | 0.43 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.42 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.41 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | CDK9 | P50750 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8281965 | 0.87 | MEN1 (0.49) | CDK8 | |
| SCHEMBL13745546 | 0.85 | CDK8 (0.56) | CDK8PDPK1MAPK14CCNT1CCNA2 | |
| SCHEMBL8281970 | 0.84 | CDK8 (0.54) | CDK8DYRK1BCLK1DYRK1APDPK1 | |
| SCHEMBL13356977 | 0.84 | CDK8 (0.48) | CDK8DYRK1BCLK1DYRK1APDPK1 | |
| SCHEMBL8280104 | 0.83 | CDK8 (0.53) | CDK8DYRK1BCLK1DYRK1AGSK3B | |
| SCHEMBL8281318 | 0.82 | ROCK2 (0.52) | DYRK1BCLK1DYRK1APDPK1GSK3B | |
| SCHEMBL8281969 | 0.82 | DYRK1B (0.61) | CDK8DYRK1BCLK1DYRK1AGSK3B | |
| SCHEMBL8281973 | 0.82 | CDK8 (0.51) | CDK8DYRK1BCLK1DYRK1APDPK1 | |
| SCHEMBL12410693 | 0.82 | CDK8 (0.58) | CDK8DYRK1BCLK1DYRK1ADYRK2 | |
| SCHEMBL2184197 | 0.80 | CDK8 (0.65) | CDK8DYRK1BCLK1DYRK1APDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110166173-A1 | 3,5-DISUBSTUTUTED 1H-PYRROLO [2,3-B] PYRIDINES AS JNK INHIBITORS | EISAI CO., LTD. (JP) | 2011-07-07 | — | — | US | disclosed |
| US-20110166173-A1 | 3,5-DISUBSTUTUTED 1H-PYRROLO [2,3-B] PYRIDINES AS JNK INHIBITORS | EISAI CO., LTD. (JP) | 2011-07-07 | — | — | US | disclosed |
| EP-1720871-B1 | 3,5-DISUBSTITUTED 1H-PYRROLO [2,3-B] PYRIDINES AS JNK INHIBITORS | EISAI R&D MAN CO LTD (JP) | 2010-05-19 | — | — | EP | disclosed |
| WO-2005085244-A1 | 3,5-DISUBSTITUTED 1H-PZRROLO [2,3-B] PYRIDINES AS JNK INHIBITORS | EISAI LONDON RESEARCH LABORATORIES LIMITED (GB) | 2005-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166173-A1 | 3,5-DISUBSTUTUTED 1H-PYRROLO [2,3-B] PYRIDINES AS JNK INHIBITORS | API5, CDK5, MAPKAPK5 | CDK8 423/4885DYRK1B 1019/4885CLK1 1193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.